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Sir: Dellinger et al. are to be con-
gratulated on their new Surviving
Sepsis Campaign recommendations
as published recently in this jour-
nal [1]. The efforts of Dellinger and
his group are of great value for all
of us who take care of patients with
sepsis. Indeed, guidelines like those
from the Surviving Sepsis Campaign,
an initiative of the European Soci-
ety of Intensive Care Medicine, the
International Sepsis Forum, and the
Society of Critical Care Medicine, are
very much welcomed and appreciated
by the intensive care community.
They have been and continue to be an
important tool in improving care of
septic patients globally.
However, in our opinion, the
new recommendations are ﬂawed
with respect to glucose control. The
new recommendations for septic
patients advise maintaining the blood
glucose concentration (BGC) below
150mg/dl (8.3mmol/l) instead of
adhering to the more strict thresholds
as in the two randomized controlled
trials by van den Berghe et al. (BGC
80–110mg/dl, 4.0–6.1mmol/l) [2, 3].
The Surviving Sepsis Campaign justi-
ﬁes this departure on several grounds:
new studies show conﬂicting results
incidence of severe hypoglycemia
with lower BGC thresholds, with
a presumed association between
severe hypoglycemia and death. We
disagree with the advised thresholds,
and argue against the reasoning for
not retaining the original stricter BGC
thresholds.
First, the evidence. Simply, there
are no studies that provide evidence
for glucose control in sepsis using
the now recommended threshold of
150mg/dl. Using the 150mg/dl upper
limit, more septic patients will be in
the higher BGC range. However, with
more successful glucose control (i.e.,
BGC closer to 80mg/dl) more beneﬁt
is achieved [4, 5]. Indeed, the lowered
BGC rather than the insulin dose is
related to reduced mortality, critical
illness polyneuropathy, bacteremia,
and inﬂammation [4].
Second, the conﬂicting infor-
mation that comes from new (yet
unpublished) studies [6, 7]. Unfor-
tunately, the multicenter VISEP trial
on glucose control in Germany by
the SepNet group was discontinued
prematurely because of identical mor-
tality rates in the treatment groups but
a higher incidence of hypoglycemia
in the glucose control group (12.1%
vs. 2.1%) [6]. Another study, the
European GLUControl trial, was also
stopped before inclusion was com-
pleted [7]. As in the VISEP study, the
primary reason for stopping inclusion
of patients was the relatively high
incidence of hypoglycemia in the
glucose control group. Due to the
early termination of these studies
we are left with two underpowered
randomized controlled trials which
can by no means be used as evidence
in the discussion on potential beneﬁt
of glucose control.
Third, blood glucose control
with insulin carries the risk of hy-
poglycemia. Indeed, the incidence
of severe hypoglycemia (deﬁned as
a blood glucose concentration
<40 mg/dl) is 5 to 10 times higher
than with a conventional blood glu-
cose strategy [2, 3]. Thus, the rise
in incidence of hypoglycemia in the
glucose control groups in the two
newer studies as mentioned above
was not surprising. Similar ﬁndings
came from numerous other studies
reporting on some form of glucose
control (merely studies with a be-
fore–after design) [8]. Fear of severe
hypoglycemia has, at least in part,
hampered broad implementation of
glucose control [8]. Although many
ICUs have adopted some form of glu-
cose control, frequently the applied
glucose control regimens have higher
thresholds than those used in the
original studies. Of note, with higher
BGC thresholds, the incidence of
severe hypoglycemia does not differ
greatly from that with more strict
BGC thresholds [8].
Fourth, the assumed association
between hypoglycemia and poor out-
come. We recently analyzedthe short-
term consequences (seizures, coma,
and death) of hypoglycemia [9]. The
hazard ratio for in-hospital death
was 1.03 (95% conﬁdence interval
0.68–1.56; P= 0.88) in patients with
a ﬁrst occurrence of hypoglycemia
relative to the controls without hy-
poglycemia. Results were corrected
for duration of intensive care unit
admittance before hypoglycemia,age,
sex, and Acute Physiology, Age and
Chronic Health Evaluation II score at
admission. In addition, no cases of
hypoglycemia-associated death were
reported.
Although the evidence for glucose
control with strict thresholds does
not yet support a grade A recom-
mendation (based on the highest
level of evidence), it does appear
to be stronger than the evidence in
support of a strategy of tolerating
higher BGC thresholds. Most impor-
tantly, however, the only evidence we
have supports a BGC threshold of
110mg/dl, not 150mg/dl.780
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